Another box ticked, and another step closer building this company into a major biotech player. Next catalyst recruitment commenced? I suspect as we move further into the P3 trial the market will realise just how undervalued this stock is, at less than $250m, for a company with such a late stage drug for such a major indication (noting that Vertex added $20b (that’s billion with a B) AUD to its market cap in the week following FDA approval for its pain drug)
Ann: Paradigm Secures Ethics Approval for Phase 3 Trial, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $170.8M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 43.0¢ | 41.5¢ | $141.6K | 337.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9738 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 76716 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |